PriceTargets.com logo

Adamis Pharmaceuticals - ADMP Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 09/7/2023 04:59 PM ET
+0 (0.00%)
Get New Adamis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADMP

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Adamis Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ADMP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Adamis Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/3/2021Dawson JamesReiterated RatingNeutral
1/22/2021Maxim GroupReiterated RatingHold
11/16/2020Maxim GroupDowngradeBuy ➝ Hold
9/23/2020Maxim GroupReiterated RatingBuy$105.00
8/24/2020Dawson JamesDowngradeBuy ➝ Neutral
8/19/2020Raymond JamesReiterated RatingHold
6/16/2020Maxim GroupReiterated RatingBuy$105.00
6/15/2020Dawson JamesUpgradeBuy$70.00
5/13/2020Maxim GroupUpgradeHold ➝ Buy$105.00
2/27/2020Dawson JamesDowngradeBuy ➝ Neutral
(Data available from 1/2/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.28
Low: $0.77
High: $3.99

52 Week Range

Now: N/A

Volume

119,800 shs

Average Volume

811,695 shs

Market Capitalization

$7.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Adamis Pharmaceuticals?

The following equities research analysts have issued research reports on Adamis Pharmaceuticals in the last year: StockNews.com.
View the latest analyst ratings for ADMP.

What is the current price target for Adamis Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Adamis Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Adamis Pharmaceuticals in the next year.
View the latest price targets for ADMP.

What is the current consensus analyst rating for Adamis Pharmaceuticals?

Adamis Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ADMP.

What other companies compete with Adamis Pharmaceuticals?

Other companies that are similar to Adamis Pharmaceuticals include Jupiter Wellness, Alvotech, Biofrontera, Clever Leaves and Cyclo Therapeutics. Learn More about companies similar to Adamis Pharmaceuticals.

How do I contact Adamis Pharmaceuticals' investor relations team?

Adamis Pharmaceuticals' physical mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company's listed phone number is (858) 997-2400 and its investor relations email address is [email protected]. The official website for Adamis Pharmaceuticals is www.adamispharmaceuticals.com. Learn More about contacing Adamis Pharmaceuticals investor relations.